The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines

The treatment of leukemias, especially acute myeloid leukemia (AML), is still a challenge as can be seen by poor 5-year survival of AML. Therefore, new therapeutic approaches are needed to increase the treatment success. Epigenetic aberrations play a role in pathogenesis and resistance of leukemia....

Descripción completa

Detalles Bibliográficos
Autores principales: Bollmann, Lukas M., Skerhut, Alexander J., Asfaha, Yodita, Horstick, Nadine, Hanenberg, Helmut, Hamacher, Alexandra, Kurz, Thomas, Kassack, Matthias U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656955/
https://www.ncbi.nlm.nih.gov/pubmed/36362189
http://dx.doi.org/10.3390/ijms232113398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656955/
https://www.ncbi.nlm.nih.gov/pubmed/36362189
http://dx.doi.org/10.3390/ijms232113398

Ejemplares similares